Asia’s vaccine self-sufficiency drive gets $650m boost

**Lead**

A major push to transform Asia into a self-sufficient vaccine manufacturing hub received a $650 million injection today, as a consortium of international development banks and philanthropic foundations announced the funding during the Global Health Security Summit in London. The money will be channelled into building new production facilities, training skilled workforces, and transferring cutting-edge mRNA and viral vector technology to countries that currently import the vast majority of their vaccines. The initiative is designed to prevent the kind of supply chaos seen during the Covid-19 pandemic, when richer nations hoarded doses while much of Asia waited months for shipments.

**Context**

Asia is home to more than 60 percent of the world’s population, but it produces less than 15 percent of the vaccines it consumes, according to industry estimates. The continent depends overwhelmingly on a handful of suppliers: India’s Serum Institute, the United States, and European pharmaceutical giants such as Pfizer and AstraZeneca. When the pandemic struck, export restrictions and bilateral deals froze many Asian nations out of the market. Countries such as Indonesia, Thailand, and Vietnam were forced to scramble for donations, while others, like Myanmar and Laos, received barely a fraction of the doses they needed.

The new funding — which brings total commitments for the Asian Vaccine Manufacturing Initiative (AVMI) to more than $1.5 billion — will target seven priority nations: Indonesia, Vietnam, Thailand, Malaysia, Bangladesh, the Philippines, and South Korea. Each of these countries already has some pharmaceutical infrastructure, but lacks the ability to produce advanced vaccines at scale. The money will support the construction of biosafety level 3 laboratories, the acquisition of single-use bioreactors, and the licensing of technology from firms in the United Kingdom and Australia. The initiative is coordinated by the Asian Development Bank in partnership with the World Health Organization, the Coalition for Epidemic Preparedness Innovations, and the Wellcome Trust.

**Analise**

The $650 million pledge signals a strategic pivot away from the old model of vaccine charity towards a system of regional resilience. For decades, global health security relied on a few centralised producers exporting to the rest of the world. That approach broke down during Covid-19 when nationalism trumped solidarity. By investing in geographically distributed manufacturing capacity, funders hope to create a buffer against future pandemics — particularly those caused by new pathogens emerging from dense animal-human interfaces in Southeast Asia.

However, the initiative faces significant hurdles. Vaccine manufacturing is not simply a matter of building factories; it requires a skilled workforce, rigorous regulatory oversight, and sustained demand sufficient to keep plants running during non-crisis periods. Many Asian governments lack the regulatory maturity to approve homegrown vaccines quickly, and there is a risk that shiny new facilities sit idle once the pandemic urgency fades. The programme therefore includes a substantial component for training regulators and establishing joint procurement mechanisms among the seven target nations. If that works, it could transform Asia from a vaccine beggar into a vaccine exporter — reducing global supply vulnerability in the long run.

For the United Kingdom, the announcement carries both opportunities and risks. British firms hold valuable intellectual property in mRNA and adenovirus vaccine platforms, and the initiative explicitly includes licensing deals with UK biotechs. That could generate revenue and soften criticism that the West has neglected the Global South’s access to life-saving technology. On the other hand, if Asian manufacturing capacity matures rapidly, it could undercut the dominance of British pharmaceutical exports to Asian markets. The UK government has quietly supported the AVMI, viewing it as a way to build diplomatic goodwill while keeping a foot in the door for future commercial partnerships.

**Fontes**

This article is based on the official announcement made at the Global Health Security Summit in London on 16 October 2026, alongside publicly available information from the Asian Development Bank, the World Health Organization, and the Coalition for Epidemic Preparedness Innovations. Data on Asia’s vaccine manufacturing capacity is drawn from the International Vaccine Institute and the Duke Global Health Innovation Center, while commentary on the UK’s strategic position reflects analysis published by the Royal Institute of International Affairs (Chatham House) and the London School of Hygiene & Tropical Medicine.